---
title: "FDA Launches Global Reliance Disclosure Program to Enhance Access to Medicines"
id: "fda-news-releases-0-fda-launches-the-global-reliance-disclosure-program-to-expand-patient-access-to"
canonical_url: "https://medichelpline.com/clinical-feed/fda-news-releases-0-fda-launches-the-global-reliance-disclosure-program-to-expand-patient-access-to"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "FDA News Releases"
source_url: "http://www.fda.gov/news-events/press-announcements/fda-launches-global-reliance-disclosure-program-expand-patient-access-medicines-worldwide"
published_at: "2026-11-17T20:32:16.000Z"
evidence_level: "Agency Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# FDA Launches Global Reliance Disclosure Program to Enhance Access to Medicines
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/fda-news-releases-0-fda-launches-the-global-reliance-disclosure-program-to-expand-patient-access-to
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** FDA News Releases
- **Source URL:** [Original Journal Publication](http://www.fda.gov/news-events/press-announcements/fda-launches-global-reliance-disclosure-program-expand-patient-access-medicines-worldwide)
- **Published At:** 2026-11-17T20:32:16.000Z
- **Evidence Rating:** Agency Feed
## Executive GIST (TL;DR)
- FDA launches the Global Reliance Disclosure Program (GRDP) to improve drug access.- Focuses on sharing approval packages internationally for faster patient access.- Initial program launched on Oct. 30, 2026, targeting HIV drug lenacapavir.- Plans to expand GRDP to all new drugs by January 2027.- Aims to harmonize global drug standards and reduce review times in lower-resource countries.
## Clinical Analysis & Structured Key Points
* [Skip to main content](https://www.fda.gov/news-events/press-announcements/fda-launches-global-reliance-disclosure-program-expand-patient-access-medicines-worldwide#main-content) * [Skip to FDA Search](https://www.fda.gov/news-events/press-announcements/fda-launches-global-reliance-disclosure-program-expand-patient-access-medicines-worldwide#search-form) * [Skip to in this section menu](https://www.fda.gov/news-events/press-announcements/fda-launches-global-reliance-disclosure-program-expand-patient-access-medicines-worldwide#section-nav) * [Skip to footer links](https://www.fda.gov/news-events/press-announcements/fda-launches-global-reliance-disclosure-program-expand-patient-access-medicines-worldwide#footer) ![U.S. flag](https://www.fda.gov/themes/custom/preview/assets/images/US_Flag.png) An official website of the United States government [Here’s how you know ](https://www.fda.gov/news-events/press-announcements/fda-launches-global-reliance-disclosure-program-expand-patient-access-medicines-worldwide) ![Dot gov](https://www.fda.gov/themes/custom/preview/assets/images/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. ![SSL](https://www.fda.gov/themes/custom/preview/assets/images/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Per [Executive Order 14434](https://www.whitehouse.gov/presidential-actions/2026/09/inaugurating-the-era-of-super-intelligence/), federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across FDA content during this transition. Learn more at [FDA’s Use of “Super Intelligence” and “SI” Under Executive Order 14434](https://www.fda.gov/science-research/fda-and-super-intelligence/fdas-use-super-intelligence-and-si-under-executive-order-14434). [ ![U.S. Food and Drug Administration logo](https://www.fda.gov/themes/custom/preview/assets/images/FDA_Logo_Icon_White.svg) ](https://www.fda.gov/ "FDA Homepage") * Search * Menu Search FDA Submit search ## Featured * [Report a Product Problem](https://contact.fda.gov/report-problem?utm_medium=referral&utm_source=fda_gov_menu "Report a Problem with an FDA Regulated Product") * [Contact FDA](https://www.fda.gov/about-fda/contact-fda) * [FDA Guidance Documents](https://www.fda.gov/regulatory-information/search-fda-guidance-documents) * [Recalls, Market Withdrawals and Safety Alerts](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts) * [Press Announcements](https://www.fda.gov/news-events/newsroom/press-announcements) * [Warning Letters](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters) * [Advisory Committees](https://www.fda.gov/advisory-committees) * [En Español](https://www.fda.gov/fda-en-espanol) ## Products * [Food](https://www.fda.gov/food) * [Drugs](https://www.fda.gov/drugs) * [Medical Devices](https://www.fda.gov/medical-devices) * [Radiation-Emitting Products](https://www.fda.gov/radiation-emitting-products) * [Vaccines, Blood, and Biologics](https://www.fda.gov/vaccines-blood-biologics) * [Animal and Veterinary](https://www.fda.gov/animal-veterinary) * [Cosmetics](https://www.fda.gov/cosmetics) * [Tobacco Products](https://www.fda.gov/tobacco-products) ## Topics * [About FDA](https://www.fda.gov/about-fda) * [Combination Products](https://www.fda.gov/combination-products) * [Regulatory Information](https://www.fda.gov/regulatory-information) * [Safety](https://www.fda.gov/safety) * [Emergency Preparedness](https://www.fda.gov/emergency-preparedness-and-response) * [International Programs](https://www.fda.gov/international-programs) * [News and Events](https://www.fda.gov/news-events) * [Training and Continuing Education](https://www.fda.gov/training-and-continuing-education) * [Inspections and Compliance](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations) * [Science and Research](https://www.fda.gov/science-research) ## Information For * [Consumers](https://www.fda.gov/consumers) * [Patients](https://www.fda.gov/patients) * [Industry](https://www.fda.gov/industry) * [Health Professionals](https://www.fda.gov/health-professionals) * [Federal, State and Local Officials](https://www.fda.gov/federal-state-local-tribal-and-territorial-officials) 1. [Home](https://www.fda.gov/) 2. [News & Events](https://www.fda.gov/news-events) 3. [FDA Newsroom](https://www.fda.gov/news-events/fda-newsroom) 4. [Press Announcements](https://www.fda.gov/news-events/fda-newsroom/press-announcements) 5. FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide 1. [ Press Announcements ](https://www.fda.gov/news-events/fda-newsroom/press-announcements "Press Announcements") [In this section](https://www.fda.gov/news-events/press-announcements/fda-launches-global-reliance-disclosure-program-expand-patient-access-medicines-worldwide#section-nav) * [ Press Announcements ](https://www.fda.gov/news-events/fda-newsroom/press-announcements "Press Announcements") FDA News Release # FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide [ More Press Announcements](https://www.fda.gov/news-events/newsroom/press-announcements) For Immediate Release: November 17, 2026 The U.S. Food and Drug Administration today announced the Global Reliance Disclosure Program (GRDP), a landmark initiative that will fundamentally transform how the FDA's regulatory drug and biologic approval decisions are leveraged by health authorities around the world. The GRDP marks a major step forward in the FDA's global leadership and may accelerate patient access to innovative therapies throughout the world. The GRDP enables the FDA to more efficiently share minimally redacted approval packages, including the FDA's detailed scientific and regulatory assessments, directly with companies who can then share them with regulatory authorities outside of the United States, empowering those authorities to rely on the FDA's rigorous, science-based review decisions rather than conducting duplicative and time-consuming product evaluations of their own, while maintaining sovereignty over their regulatory decision. "The GRDP is a prime example of America First policies improving public health worldwide," **said Grace Graham, FDA Deputy Commissioner for Policy, Legislation, and International Affairs**. "The FDA is the global gold standard and making it easier for applicants to leverage our detailed scientific assessments to facilitate faster access for patients everywhere is an example of America’s continued interest in advancing global health under the Trump Administration." The GRDP launched on Oct. 30, with a [President's Emergency Plan for AIDS Relief](https://www.fda.gov/international-programs/presidents-emergency-plan-aids-relief-pepfar "President's Emergency Plan for AIDS Relief \(PEPFAR\)") (PEPFAR) tentative approval for [lenacapavir](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=221496), a drug indicated for both HIV prevention and treatment. This is an especially meaningful starting point given PEPFAR's life-saving mission to combat HIV/AIDS in some of the world's most vulnerable populations. The GRDP is currently available to PEPFAR tentative approvals, excluding tentatively approved abbreviated new drug application products. However, the FDA intends to expand the GRDP in January 2027 to all novel drug and biologics (New Molecular Entity New Drug Applications and 351(a) Biologics License Applications), dramatically broadening the program's reach and impact. The FDA also intends to launch a pathway in early 2027 to expedite an applicant’s ability to request their minimally redacted action packages for approved and licensed drugs and biologics, accelerating global access to medicines that are already on the market in the United States and have been found to be safe and effective by the FDA. To receive a minimally redacted application approval package as part of the GRDP, applicants must request to participate within 10 calendar days of approval and confirm the application package is being submitted to a foreign regulatory authority in support of a marketing application. Applicants with eligible GRDP applications will receive detailed information in FDA approval letters and the agency intends to provide the minimally redacted package on an expedited basis. Requests for minimally redacted approval packages for other purposes will not be processed under the GRDP and should be submitted as a Freedom of Information Act (FOIA) request. “In an era of increasing global interdependence in pharmaceutical development and supply chains, the FDA's leadership is most effective when it is collaborative,” **said Mark Abdoo, FDA Associate Commissioner for Global Policy and Strategy**. “The GRDP reflects a forward-looking vision of regulatory leadership: one defined not by exclusivity, but by the willingness to share expertise, elevate global standards, and put patients first — wherever they are.” The GRDP addresses one of the most persistent and consequential challenges in global health: the gap between regulatory approval in high-capacity countries and patient access in lower-resource settings. When a drug is approved by the FDA, patients in many parts of the world may wait months or years longer for their own national health authority to complete an independent review due to limited regulatory capacity and resources. Beyond individual product approvals, the GRDP supports global health security. Harmonized regulatory decisions reduce the risk of fragmented or inconsistent product standards across markets, helping to ensure that the same high-quality therapies reach patients regardless of where they live, including here in the United States. * * * **Media:** [FDA Request for Comment](https://www.hhs.gov/request-for-comment-form/index.html?Agency=FDA) 202-690-6343 **Consumer:** 888-INFO-FDA The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products. ### * * * * ## Content current as of: 11/17/2026 * ## Regulated Product(s) * Drugs * ## Follow FDA * [ Follow @US_FDA on X ](https://x.com/FDA)[External Link Disclaimer](http://www.fda.gov/about-fda/website-policies/website-disclaimer) * [Follow FDA on Facebook](https://www.facebook.com/FDA)[External Link Disclaimer](http://www.fda.gov/about-fda/website-policies/website-disclaimer) * [ Follow @FDAMedia on X ](https://x.com/FDAMedia)[External Link Disclaimer](http://www.fda.gov/about-fda/website-policies/website-disclaimer) ## Feedback form ### Success Thank you. Your feedback has been received. ### Error alert message Was this page helpful? * Yes No Submit ![U.S. flag](https://touchpoints.app.cloud.gov/img/us_flag_small.png) An official form of the United States government. Provided by [Touchpoints](https://touchpoints.digital.gov) Feedback * [FDA Archive](https://www.fda.gov/about-fda/about-website/fdagov-archive) * [About FDA](https://www.fda.gov/about-fda) * [Accessibility](https://www.fda.gov/about-fda/about-website/internet-accessibility) * [Visitor Information](https://www.fda.gov/about-fda/visitor-information) * [Website Policies / Privacy](https://www.fda.gov/about-fda/about-website/website-policies) * [No FEAR Act](https://www.fda.gov/about-fda/jobs-and-training-fda/no-fear-act) * [Vulnerability Disclosure Policy](https://www.hhs.gov/vulnerability-disclosure-policy/index.html) * [FOIA](https://www.fda.gov/regulatory-information/freedom-information "Freedom of Information Act") * [HHS.gov](https://www.hhs.gov/ "Health and Human Services") * [USA.gov](https://www.usa.gov/) [Contact FDA](https://www.fda.gov/about-fda/contact-fda) [ Follow FDA on Facebook ](https://www.facebook.com/FDA "Follow FDA on Facebook") [ Follow FDA on X ](https://x.com/FDA "Follow FDA on X") [ Follow FDA on Instagram ](https://instagram.com/FDA "Follow FDA on Instagram") [ Follow FDA on LinkedIn ](https://www.linkedin.com/company/fda/ "Follow FDA on LinkedIn") [ View FDA videos on YouTube ](https://youtube.com/@US_FDA "View FDA videos on YouTube") [ Subscribe to FDA RSS feeds ](https://www.fda.gov/about-fda/contact-fda/subscribe-podcasts-and-news-feeds "Subscribe to FDA RSS feeds") [ ![Food and Drug Administration Logo](https://www.fda.gov/themes/custom/preview/assets/images/FDA_Logo_Icon_White.svg) ](https://www.fda.gov/ "FDA Homepage") Contact Number 1-888-INFO-FDA (1-888-463-6332) [Back to Top](https://www.fda.gov/news-events/press-announcements/fda-launches-global-reliance-disclosure-program-expand-patient-access-medicines-worldwide) ![U.S. Department of Health and Human Services logo](https://cg-1b082c1b-3db7-477f-9ca5-bd51a786b41e.s3-us-gov-west-1.amazonaws.com/uploads/form/logo/6295/tag_FDA_logo\(2\).png) ## FDA.gov Site Customer Feedback Help us improve FDA.gov! We will use your responses to improve the experience for millions of people who visit FDA.gov. A red asterisk (*) indicates a required field. ### Success Thank you. Your feedback has been received. ### Error alert message 1. Which of the following best categorizes the information you were looking for on FDA.gov today? * Select one Food Drugs Medical Devices Radiation-Emitting Products Vaccines, Blood & Biologics Animal & Veterinary Cosmetics Tobacco Products Other 2. Which of the following best describes the information you were looking for on FDA.gov today? * Select one Recall or foodborne illness outbreak information Warning letters or enforcement actions Report a problem (adverse event) with a product Dispose of drugs or sharps Product approvals Drug labels Side effects of a product Contact an FDA office or staff member Complete or check registration for a product or facility Get FDA organizational information Import or export a product (including Prior Notice) Get a job with FDA Get training Get a form Comment on a proposed guidance or rule Check a regulation, rule, or guidance (for regulated industry) COVID-19 information Advice/information about a medical device, drug, food, or other FDA-regulated product Other 3. Did you find the information you were looking for on FDA.gov today? * Yes Partially. I found some of the information I was looking for. No I'm still looking 4. For this visit to the FDA site, which of the following roles best describes you? If you are a consultant or an attorney, please select the role of the individual or organization that you represent. * Select one Consumer, patient, or patient’s caregiver Regulated industry or business Healthcare professional (includes physician, nurse, physician’s assistant, nurse practitioner, or pharmacist) Public health/Policy professional Scientist, researcher Educator, professor, teacher, or student Media/Journalist FDA Employee/Contractors Other 5. How frequently do you visit FDA.gov? * This is my first time About once a year A couple of times a year Monthly Weekly Daily 6. On a scale from 0-10, based on your experience today, how likely are you to recommend this website to a friend or colleague? * 0 1 2 3 4 5 6 7 8 9 10 7) Overall, how satisfied or dissatisfied were you with your experience on the FDA website today? Navigation * Very satisfied Somewhat satisfied Neither satisfied or dissatisfied Somewhat dissatisfied Very dissatisfied Look & Feel * Very satisfied Somewhat satisfied Neither satisfied or dissatisfied Somewhat dissatisfied Very dissatisfied Using FDA’s search feature * Very satisfied Somewhat satisfied Neither satisfied or dissatisfied Somewhat dissatisfied Very dissatisfied Understandability of the content * Very satisfied Somewhat satisfied Neither satisfied or dissatisfied Somewhat dissatisfied Very dissatisfied Overall Experience * Very satisfied Somewhat satisfied Neither satisfied or dissatisfied Somewhat dissatisfied Very dissatisfied Submit ![U.S. flag](https://touchpoints.app.cloud.gov/img/us_flag_small.png) An official form of the United States government. Provided by [Touchpoints](https://touchpoints.digital.gov) OMB Approval #0910-0360 · Expiration Date 07/08/2026 *[*]: required
## Related Clinical Research

- [Novartis discloses previously unknown tumors in children treated for spinal muscular atrophy](https://medichelpline.com/clinical-feed/stat-news-2-stat-pharmalittle-we-re-reading-about-a-novartis-gene-therapy-faster-u-k-drug.md)
- [PhRMA spent $59M on search ads to shape views of drug pricing](https://medichelpline.com/clinical-feed/stat-news-0-stat-pharma-s-trade-group-spent-heavily-on-search-ads-to-sway-public-opinion.md)
- [U.S. POINTER: Structured lifestyle program slows brain aging and cardiometabolic risk over 24 mont](https://medichelpline.com/clinical-feed/medical-news-today-0-combining-physical-mental-and-social-habits-slows-brain-aging-in-2-year-trial.md)
- [Governments pledge 230+ new commitments to prevent violence against children](https://medichelpline.com/clinical-feed/who-0-0-governments-make-over-230-new-pledges-to-prevent-violence-against-children.md)
- [Integrated cervical cancer prevention and care for women and girls living with HIV](https://medichelpline.com/clinical-feed/who-0-3-advocating-for-stronger-integrated-cervical-cancer-prevention-and-care-for.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.